Chiesi's Phase III study completed – aiming to be the first with only climate-friendly spray inhalers

HOME > > Chiesi's Phase III...
print.png
email.png

Authorize the processing of personal data
Edit email address
Invalid email
Email Sent
Authorize the processing of personal data
BACK TO LIST
Date: 26/09/2025

-

© 2026 Chiesi Pharma AB
Klara Norra kyrkogata 34, 111 22 Stockholm
Telefon +46 8 753 35 20
E-post infonordic@chiesi.com

R&D, Global Rare Diseases
Chiesi Pharma AB, Scheeles väg 2, 171 65 Solna
Telefon + 46 8 753 35 20
Updated at 26/09/2025
CHIESI ON THE WEB
mappa.png